October 24, 2018 Interview with Michael Scholl of Leukocare
Back in February 2017, CDMO Rentschler Biopharma SE and formulation specialist Leukocare AG joined forces to give biologics and biosimilar makers a competitive edge through signifi cantly stabilised end products. European Biotechnology spoke with Leukocare’s CEO Michael Scholl about the impact of formulation on drug product Performance.
Please find the full interview here.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication